H. Bourgeois

L. Campion, E. Vaucel, A. Lortholary, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

M. Espié, F. Bidard, J. Pierga, 2020, JAMA oncology.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Sarcopenia in metastatic cancer patients: results of a prospective non-randomized study.

E. Voog, F. Denis, A. Septans, 2021 .

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer

T. Delozier, A. Monnier, E. Gamelin, 2003, British Journal of Cancer.

A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer

T. Bachelot, R. Largillier, A. Lortholary, 2011, Breast Cancer Research and Treatment.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

L. Fallowfield, Y. Fujiwara, J. Jassem, 2012, Clinical Cancer Research.

Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study.

E. Pujade-Lauraine, M. Fabbro, H. Curé, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials

Chunlei Ke, Alison T Stopeck, David H. Henry, 2011 .

Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.

D. Berton, D. Spaeth, I. Ray-Coquard, 2022, Gynecologic oncology.

The place of the relative at the time of the announcement of cancer progression. BABEL, a mixed-method study

P. Colombat, I. Ingrand, E. Gyan, 2022 .

High dose chemotherapy in ovarian cancer

J. Lotz, E. Pujade-Lauraine, M. Fabbro, 2001, Oncology.

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.

D. Berton, I. Vergote, S. Pignata, 2020 .

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer

M. Espié, M. Campone, J. Cortés, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

R. Kimmig, B. Weber, S. Costa, 2003 .

High dose chemotherapy in ovarian cancer

J. Lotz, E. Pujade-Lauraine, M. Fabbro, 2001, International Journal of Gynecologic Cancer.

Physical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 Trial

C. Letellier, S. Boyas, F. Denis, 2022, JMIR research protocols.

Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer

P. Solal-Céligny, L. Campion, E. Voog, 2017, Supportive Care in Cancer.

Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma. Results of the 94.01 randomized study from the french group of radiation oncology for head and neck cancer (Gortec)

G. Calais, C. Sire, J. Tortochaux, 1998 .

Efficacy and tolerability of the ifosfamide–epirubicin combination in relapsed ovarian cancer

A. Floquet, F. Joly, D. Lebrun, 2004, International Journal of Gynecologic Cancer.

Should patients with advanced sarcomas be treated with chemotherapy? .

R. Benjamin, H. Bourgeois, J. Rouëssé, 1998, European journal of cancer.

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

M. Campone, F. Bidard, J. Pierga, 2021, British Journal of Cancer.

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

J. Nemunaitis, L. Wyrwicz, Keun-Wook Lee, 2018, Journal of Immunotherapy for Cancer.

Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.

B. Weber, E. Pujade-Lauraine, A. Lortholary, 2009, Anticancer research.

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.

B. Weber, F. Mayer, J. Ferrero, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO

C. Schade-Brittinger, B. Weber, C. Jackisch, 2005 .

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer

S. Pignata, G. Scambia, A. Casado, 2020, The oncologist.

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

B Richter, I Vergote, V. Gebski, 2011, British Journal of Cancer.

Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile: A Phase 2 Trial

Thierry Petit, Sophie Krieger, Nicolas Richard, 2012, International Journal of Gynecologic Cancer.

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

J. Robertson, H. Kennecke, P. Kaufman, 2013, The Lancet. Oncology.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

H. Blanché, M. Mathieu, H. Bonnefoi, 2017, npj Breast Cancer.

Proposal of a new option in pain prevention with a therapeutic virtual reality solution in bone marrow biopsy context: results of an open-label randomized multicenter phase III protocol (REVEH Trial). (Preprint)

F. Maloisel, F. Denis, A. Septans, 2022, Journal of Medical Internet Research.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

Gemcitabine, Ifosfamide, and Cisplatin Combination (GIP) in Treatment of Patients With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer: Results of a Phase II Study

D. Planchard, P. Blanc, D. Genet, 2006, American journal of clinical oncology.

Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.

I. Bièche, G. MacGrogan, L. Mauriac, 2007, Anticancer research.

Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice.

X. Pivot, S. Dewas, E. Curtit, 2019, Breast.

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

C. Letellier, O. Molinier, P. Solal-Céligny, 2017, Journal of the National Cancer Institute.

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

L. Zelek, B. Chauffert, F. Scotté, 2021, The oncologist.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.

V. Diéras, J. Misset, C. Jasmin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel Plus 5-Fluorouracil in Locally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Multicenter Study

G. Calais, D. Cupissol, J. Dutin, 2004, American journal of clinical oncology.

Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect)

E. Voog, F. Denis, Y. Pointreau, 2018, Supportive Care in Cancer.

First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.

B. Ramaswamy, K. Blackwell, J. Sparano, 2017 .

19PRibociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden

S. Verma, M. Campone, J. Kattan, 2017 .

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

M. Espié, F. Bidard, J. Pierga, 2019, General Session Abstracts.

Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.

T. Petit, F. Mayer, F. Joly, 2009, Gynecologic oncology.

Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial

B. Weber, F. Mayer, J. Ferrero, 2004 .

Handgrip fatiguing exercise can provide objective assessment of cancer-related fatigue: a pilot study

S. Boyas, B. Morel, S. Durand, 2018, Supportive Care in Cancer.

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

M. Namer, J. Bonneterre, L. Mauriac, 1999, European journal of cancer.

Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.

T. Delozier, B. Asselain, J. Canon, 2006, Journal of Clinical Oncology.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

M. Espié, D. Cox, R. Rouzier, 2016, Bulletin du cancer.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

G. Thomas, D. Cox, H. Blanché, 2016, Oncotarget.

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

E. Blot, P. Ingrand, J. Douillard, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sexual quality of life evaluation after treatment among women with breast cancer under 35 years old

O. Capitain, Y. Pointreau, H. Bourgeois, 2018, Supportive Care in Cancer.

Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours

R. Stupp, L. Nguyen, P. Fumoleau, 2007, Cancer Chemotherapy and Pharmacology.

Original Paper EYcacy and Safety of Docetaxel (Taxotere 2 ) in Heavily Pretreated Advanced Breast Cancer Patients: the French Compassionate Use Programme Experience

M. Namer, J. Bonneterre, L. Mauriac, 1999 .

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.

J. Nemunaitis, L. Wyrwicz, Keun-Wook Lee, 2018 .

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Abstract P6-14-01: Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase

J. Jassem, A. Stopeck, J. Body, 2010 .

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics

J. Douillard, P. Langlet, E. Jobard, 2014, Oncologie.

Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results.

C. Letellier, E. Basch, O. Molinier, 2018 .

Influence of an Adapted Physical Activity Program on Self-Esteem and Quality of Life of Breast Cancer Patients after Mastectomy

S. Boyas, Y. Pointreau, H. Bourgeois, 2018, Oncology.

Neuromuscular, Psychological, and Sleep Predictors of Cancer-Related Fatigue in Cancer Patients.

B. Morel, N. Peyrot, A. Rahmani, 2020, Clinical breast cancer.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

D. Cox, H. Bonnefoi, G. Romieu, 2017, European journal of cancer.

Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer

T. Delozier, F. Joly, E. Gamelin, 2006, American journal of clinical oncology.

299PEribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort

M. Campone, X. Pivot, O. Trédan, 2017 .

Phase I Study With Dose Escalation of Gemcitabine and Cisplatin in Combination With Ifosfamide (GIP) in Patients With Non–Small-Cell Lung Carcinoma

J. Meurice, H. Bourgeois, J. Tourani, 2004, American journal of clinical oncology.

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer

R. Neuwirth, J. Canon, K. Galinsky, 2021, Clinical Cancer Research.

A new option in pain prevention with bliss, a therapeutic virtual reality solution in bone marrow biopsy context: Results of a French open-label multicenter randomized phase II/III study (REVEH Trial).

S. Bouchard, F. Denis, A. Schmitt, 2021 .

Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial.

C. Letellier, O. Molinier, P. Solal-Céligny, 2016 .

P347 Benefit of denosumab therapy in patients with bone metastases from breast cancer: A number-needed-to-treat (NNT) analysis

K. Inoue, A. Stopeck, G. Steger, 2011 .

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

R. Neuwirth, J. Canon, J. Diamond, 2019, Poster Discussion Abstracts.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract OT3-3-04: ALOPREV: first cooling scalp trial for prevention of persisting alopecia after docetaxel for early breast cancer patients.

E. Blot, A. Zannetti, P. Soulié, 2012 .

Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum-based chemotherapy: A French FEDEGYN-FNCLCC phase II trial.

B. Weber, F. Joly, M. Henry-Amar, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory.

F. Denis, P. Kerbrat, J. Metges, 2009 .